Severe epistaxis related to intravitreal bevacizumab

Acta Ophthalmol. 2020 Feb;98(1):e137. doi: 10.1111/aos.14176. Epub 2019 Jun 24.

Authors

Leila S Otten¹, Madelon H Butterhoff-Terlingen², Verena C Mulder^{3

4}, Willemien Lagas-de Graaf², Angela M van der Hage-Lie⁵, Paul D van der Linden²

Affiliations

¹ Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
² Department of Clinical Pharmacy, Tergooi Hospital, Hilversum, The Netherlands.
³ Rotterdam Ophthalmic Institute, Rotterdam Eye Hospital, Rotterdam, The Netherlands.
⁴ Department of Clinical Pharmacy, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
⁵ Department of Ophthalmology, Tergooi Hospital, Hilversum, The Netherlands.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Angiogenesis Inhibitors / administration & dosage
Angiogenesis Inhibitors / adverse effects
Bevacizumab / administration & dosage
Bevacizumab / adverse effects*
Epistaxis / chemically induced*
Female
Humans
Intravitreal Injections
Macular Degeneration / drug therapy
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
Bevacizumab
Receptors, Vascular Endothelial Growth Factor